Captodiame

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Captodiame
Captodiame.svg
Systematic (IUPAC) name
2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethylethanamine
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
  • ℞ (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Excretion Renal
Identifiers
CAS Number 486-17-9 YesY
ATC code N05BB02 (WHO)
PubChem CID: 10240
DrugBank DB09014 N
ChemSpider 9823 YesY
UNII H93K9455DD YesY
KEGG D07316 YesY
Chemical data
Formula C21H29NS2
Molecular mass 359.594 g/mol
  • S(c1ccc(cc1)C(SCCN(C)C)c2ccccc2)CCCC
  • InChI=1S/C21H29NS2/c1-4-5-16-23-20-13-11-19(12-14-20)21(24-17-15-22(2)3)18-9-7-6-8-10-18/h6-14,21H,4-5,15-17H2,1-3H3 YesY
  • Key:IZLPZXSZLLELBJ-UHFFFAOYSA-N YesY
 NYesY (what is this?)  (verify)

Captodiame (INN), also known as captodiamine, is an antihistamine sold under the trade names Covatine, Covatix, and Suvren which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine.[1]

A 2004 study suggested captodiame may be helpful in preventing benzodiazepine withdrawal syndrome in people discontinuing benzodiazepine treatment.[1]

In addition to its actions as an antihistamine, captodiamine has been found to act as a 5-HT2C receptor antagonist and σ1 receptor and D3 receptor agonist.[2] It produces antidepressant-like effects in rats.[2] However, captodiamine is unique among antidepressant-like drugs in that it increases brain-derived neurotrophic factor (BDNF) levels in the hypothalamus but not in the frontal cortex or hippocampus.[2] This unique action may be related to its ability to attenuate stress-induced anhedonia and corticotropin-releasing factor (CRF) signaling in the hypothalamus.[2]

Synthesis

The oxygen atom in these molecules can in many cases be dispensed with as well; substitution of sulfur for nitrogen affords a molecule whose salient biologic properties are those of a sedative and tranquilizer.

Captodiamine synthesis: Hubner Oluf Herman, Petersen Povl Viggo. U.S. Patent 2,830,088 (1958).

Friedel-Crafts acylation of the n-butyl ether of thiophenol with benzoyl chloride gives the corresponding benzophenone. Reduction of the ketone with zinc/NaOH followed by treatment with HCl in ether affords the benzhydryl chloride. Displacement of the halogen with thiourea gives, by reaction of the last at its most nucleophilic center, the isothiouronium salt. Hydrolysis of the salt leads to the sulfur analog of a benzhydrol. Alkylation of the sodium salt of this last with N-(2-chloroethyl)dimethylamine affords captodiame.

See also

References

  1. 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found. Free full text with registration
  2. 2.0 2.1 2.2 2.3 Lua error in package.lua at line 80: module 'strict' not found.